Florian Clatot

4.0k total citations
99 papers, 1.6k citations indexed

About

Florian Clatot is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Florian Clatot has authored 99 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 38 papers in Cancer Research and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Florian Clatot's work include Cancer Genomics and Diagnostics (25 papers), Head and Neck Cancer Studies (18 papers) and Breast Cancer Treatment Studies (14 papers). Florian Clatot is often cited by papers focused on Cancer Genomics and Diagnostics (25 papers), Head and Neck Cancer Studies (18 papers) and Breast Cancer Treatment Studies (14 papers). Florian Clatot collaborates with scholars based in France, Belgium and Italy. Florian Clatot's co-authors include Frédéric Di Fiore, Matteo Lambertini, Isabelle Demeestere, Zuzana Saidak, Fabrice Jardin, Nasrin Sarafan‐Vasseur, Maxime Fontanilles, Anne Perdrix, Romain Modzelewski and Antoine Galmiche and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Florian Clatot

94 papers receiving 1.5k citations

Peers

Florian Clatot

ONCOL

PRM

PHYSI

Gro Wiedswang Norway

Stuart McIntosh United Kingdom

Beyhan Ataseven Germany

Barry R. DeYoung United States

Miriam Tucker United States

Aurélie Bertaut France

Annette Fisseler‐Eckhoff Germany

Jonathan Keith Killian United States

Catherine Shannon Australia

André Baruchel France

Gro Wiedswang Norway

Florian Clatot

1.1k ×1.6

ONCOL

763 ×1.7

338 ×0.8

PRM

374 ×1.2

88 ×0.4

PHYSI

Citations per year, relative to Florian Clatot Florian Clatot (= 1×) peers Gro Wiedswang

Countries citing papers authored by Florian Clatot

Since Specialization

Citations

This map shows the geographic impact of Florian Clatot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Clatot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Clatot more than expected).

Fields of papers citing papers by Florian Clatot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian Clatot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Clatot. The network helps show where Florian Clatot may publish in the future.

Co-authorship network of co-authors of Florian Clatot

This figure shows the co-authorship network connecting the top 25 collaborators of Florian Clatot. A scholar is included among the top collaborators of Florian Clatot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Clatot. Florian Clatot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruminy, Philippe, et al.. (2025). Prognostic value of circulating HER2 extracellular domain in patients with HER2-positive metastatic breast carcinoma treated with TDM-1 (trastuzumab emtansine). Clinical & Translational Oncology. 28(2). 711–718. 1 indexed citations

Perdrix, Anne, et al.. (2025). Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy. Breast Cancer Research and Treatment. 212(1). 79–86. 2 indexed citations

Perdrix, Anne, Anne Rovelet‐Lecrux, Nasrin Sarafan‐Vasseur, et al.. (2024). Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer. Frontiers in Oncology. 14. 1382008–1382008. 2 indexed citations

Fayette, Jérôme, Florian Clatot, Irene Braña, et al.. (2024). Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 6014–6014. 12 indexed citations

Alexandru, Cristina, Isabelle Tennevet, Olivier Langlois, et al.. (2024). Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients. Translational Oncology. 42. 101897–101897. 1 indexed citations

Thomssen, Christoph, Martina Vetter, Eva Johanna Kantelhardt, et al.. (2023). Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. Cancers. 15(5). 1580–1580.

Beaussire, Ludivine, Marianne Leheurteur, Cécile Guillemet, et al.. (2023). Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma. BMC Cancer. 23(1). 1061–1061. 5 indexed citations

Anderson, Richard A., et al.. (2022). Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer. Breast Cancer Research and Treatment. 192(2). 273–282. 10 indexed citations

Clatot, Florian, et al.. (2022). Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients. European Archives of Oto-Rhino-Laryngology. 280(5). 2453–2461. 6 indexed citations

10.

Anderson, Richard A., David Cameron, Florian Clatot, et al.. (2022). Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Human Reproduction Update. 28(3). 417–434. 61 indexed citations

11.

Buisseret, Laurence, Delphine Loirat, Kevin Punie, et al.. (2022). LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). Annals of Oncology. 33. S1385–S1385. 7 indexed citations

12.

Turan, Volkan, Matteo Lambertini, Dong‐Yun Lee, et al.. (2021). Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. Journal of Clinical Oncology. 39(18). 2016–2024. 41 indexed citations

13.

Fontanilles, Maxime, et al.. (2021). Place des biopsies liquides dans le diagnostic et la caractérisation moléculaire des cancers du sein. Bulletin du Cancer. 108(11). 11S46–11S54.

14.

Richard, François, Samira Majjaj, David Venet, et al.. (2020). Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research. 26(23). 6254–6265. 19 indexed citations

15.

Anderson, Richard A., Florian Clatot, Isabelle Demeestere, et al.. (2020). Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. European Journal of Cancer. 144. 310–316. 34 indexed citations

16.

Saidak, Zuzana, Antoine Galmiche, Simon Soudet, et al.. (2020). The coagulome of Head and Neck Squamous Cell Carcinoma. Oral Oncology. 114. 105068–105068. 3 indexed citations

17.

Bourhis, Jean, C. Le Tourneau, Y. Pointreau, et al.. (2020). LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 31. S1168–S1168. 5 indexed citations

18.

Perdrix, Anne, Justine Lequesne, Maxime Fontanilles, et al.. (2020). 265P Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients. Annals of Oncology. 31. S344–S345. 1 indexed citations

19.

Beaussire, Ludivine, Anne Perdrix, David Sefrioui, et al.. (2017). Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Annals of Oncology. 28. v58–v58. 3 indexed citations

20.

Clatot, Florian, Marie Cornic, Liana Veresezan, et al.. (2015). Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors. American Journal of Clinical Pathology. 144(4). 555–562. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact